Yufang Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yufang Zhou has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Aixiang Xiao
Department of Nursing Administration, Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China
1 shared publication - Claire Papaix
Department of Management of Economy, Human Resources, Information Systems and Diversity, Montpellier Business School, 34080 Montpellier, France
1 shared publication G. F. Si
Department of Pharmacy, Anhui University of Chinese Medicine, 230012, Hefei, P.R. China
1 shared publicationG. Y. Xu
Institutes of Physical Science and Information Technology, Anhui University, 230601, Hefei, P.R. China
1 shared publicationGuoan Ding
Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
1 shared publicationJ. F. Wang
Department of Pharmacy, Anhui University of Chinese Medicine, 230012, Hefei, P.R. China
1 shared publication
Latest Publications
- 10 July 2023
- Published by Taylor & Francis
- p. 363-382
Urban mobility and mobility-as-a-service (MaaS) trends
The growth of tourism has increased the need for visitors to negotiate foreign languages, unknown transport systems, complex networks, asynchronous payment methods, and different currencies in tourism destinations, which has added to travel stress. This chapter explores the use of mobility-as-a-service (MaaS), a digital innovation designed to manage urban mobility trips, as a solution to improve tourists wellbeing. Beijing MaaS was developed in 2019 in China, alongside the city’s carbon trade incentive approach, to contribute to the city’s 2030 carbon-neutral target and enhance visitors’ wellbeing and levels of satisfaction related to travel. This chapter presents users’ attitudes towards Beijing MaaS in 2020 and 2021. It explores tourists’ concerns, needs, and values towards tourism and MaaS in this particular case study, compared to other places in the world. The authors conclude that MaaS has considerable potential to improve tourists’ wellbeing through providing instant and accessible travel information into a seamless, convenient, and user-centric mobility service.
- 10 July 2023
- Published by Taylor & Francis
- p. 363-382
Urban mobility and mobility-as-a-service (MaaS) trends
The growth of tourism has increased the need for visitors to negotiate foreign languages, unknown transport systems, complex networks, asynchronous payment methods, and different currencies in tourism destinations, which has added to travel stress. This chapter explores the use of mobility-as-a-service (MaaS), a digital innovation designed to manage urban mobility trips, as a solution to improve tourists wellbeing. Beijing MaaS was developed in 2019 in China, alongside the city’s carbon trade incentive approach, to contribute to the city’s 2030 carbon-neutral target and enhance visitors’ wellbeing and levels of satisfaction related to travel. This chapter presents users’ attitudes towards Beijing MaaS in 2020 and 2021. It explores tourists’ concerns, needs, and values towards tourism and MaaS in this particular case study, compared to other places in the world. The authors conclude that MaaS has considerable potential to improve tourists’ wellbeing through providing instant and accessible travel information into a seamless, convenient, and user-centric mobility service.
- Open Access
- 28 June 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-8
Repeated use of SSRIs potentially associated with an increase on serum CK and CK-MB in patients with major depressive disorder: a retrospective study
There is a large amount of evidence that selective serotonin reuptake inhibitors (SSRIs) are related to cardiovascular toxicity, which has aroused concern regarding their safety. However, few studies have evaluated the effects of SSRIs on cardiac injury biomarkers, such as creatine kinase (CK) and creatine kinase isoenzyme (CK-MB). The purpose of our study was to determine whether SSRIs elevated CK and CK-MB levels of prior medicated depressive patients (PMDP) compared to first-episode drug-naïve depressive patients (FDDPs). We performed an observational and retrospective study involving 128 patients with major depressive disorder. Patients who had never used any type of antidepressant were designated FDDP; patients who had used only one type of SSRI but were not treated after a recent relapse were designated PMDP. Serum CK and CK-MB levels were measured before and after using SSRIs for a period of time. The duration of current treatment in the FDDP and PMDP groups was 16.200 ± 16.726 weeks and 15.618 ± 16.902 weeks, respectively. After SSRI treatment, levels of serum CK in the PMDP group were significantly higher than in the FDDP group. Univariate ANCOVA results revealed that PMDP was 22.313 times more likely to elevate CK (OR 22.313, 95% CI 9.605–35.022) and 2.615 times more likely to elevate CK-MB (OR 2.615, 95% CI 1.287–3.943) than FDDP. Multivariate ANCOVA revealed an interaction between the group and sex of CK and CK-MB. Further pairwise analysis of the interaction results showed that in female patients, the mean difference (MD) of CK and CK-MB in PMDP was significantly greater than that in FDDP (MD = 33.410, P = 0.000, 95% CI 15.935–50.886; MD = 4.613, P = 0.000, 95% CI 2.846–6.381). Our findings suggest that patients, especially females, who had previously used SSRI antidepressants were more likely to have elevated CK and CK-MB, indicators of myocardial muscle injury. Use of SSRIs should not be assumed to be completely safe and without any cardiovascular risks.
- 28 June 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-8
Open AccessRepeated use of SSRIs potentially associated with an increase on serum CK and CK-MB in patients with major depressive disorder: a retrospective study
There is a large amount of evidence that selective serotonin reuptake inhibitors (SSRIs) are related to cardiovascular toxicity, which has aroused concern regarding their safety. However, few studies have evaluated the effects of SSRIs on cardiac injury biomarkers, such as creatine kinase (CK) and creatine kinase isoenzyme (CK-MB). The purpose of our study was to determine whether SSRIs elevated CK and CK-MB levels of prior medicated depressive patients (PMDP) compared to first-episode drug-naïve depressive patients (FDDPs). We performed an observational and retrospective study involving 128 patients with major depressive disorder. Patients who had never used any type of antidepressant were designated FDDP; patients who had used only one type of SSRI but were not treated after a recent relapse were designated PMDP. Serum CK and CK-MB levels were measured before and after using SSRIs for a period of time. The duration of current treatment in the FDDP and PMDP groups was 16.200 ± 16.726 weeks and 15.618 ± 16.902 weeks, respectively. After SSRI treatment, levels of serum CK in the PMDP group were significantly higher than in the FDDP group. Univariate ANCOVA results revealed that PMDP was 22.313 times more likely to elevate CK (OR 22.313, 95% CI 9.605–35.022) and 2.615 times more likely to elevate CK-MB (OR 2.615, 95% CI 1.287–3.943) than FDDP. Multivariate ANCOVA revealed an interaction between the group and sex of CK and CK-MB. Further pairwise analysis of the interaction results showed that in female patients, the mean difference (MD) of CK and CK-MB in PMDP was significantly greater than that in FDDP (MD = 33.410, P = 0.000, 95% CI 15.935–50.886; MD = 4.613, P = 0.000, 95% CI 2.846–6.381). Our findings suggest that patients, especially females, who had previously used SSRI antidepressants were more likely to have elevated CK and CK-MB, indicators of myocardial muscle injury. Use of SSRIs should not be assumed to be completely safe and without any cardiovascular risks.
- 1 January 2021
- Published by Pleiades Publishing Ltd in Russian Journal of Coordination Chemistry
- Vol. 47 (1) , 66-74
Preparation, Two-Photon Absorption, and Bioimaging Application of a Curcumin-Based Copper(II) Complex
A new multi-branched model Cu(II) complex based on curcumin, namely CuL2(I) (НL = (1E,4Z,6E)-1,7-bis(4-(4-bromobutoxy)-3-methoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one, C29H34O6Br2), was prepared and its two-photon absorption (TPA) properties were described in the femtosecond regime. The experimental results showed that complex I exhibited relatively strong and wide-dispersed two-photon activities in the near-infrared (NIR) regime and the calculated TPA cross section of complex I was as high as 872 GM (1 GM = 10−50 cm4 s photon−1) in DMF. Additionally, complex I revealed its potential application as a biological fluorescent probe due to its good photo-physical properties and low cytotoxicity, as well as excellent stability and specificity for optical imaging of tumors. Complex I was characterized by single crystal X-ray diffraction too (CIF file CCDC no. 1412447).
- 1 January 2021
- Published by Pleiades Publishing Ltd in Russian Journal of Coordination Chemistry
- Vol. 47 (1) , 66-74
Preparation, Two-Photon Absorption, and Bioimaging Application of a Curcumin-Based Copper(II) Complex
A new multi-branched model Cu(II) complex based on curcumin, namely CuL2(I) (НL = (1E,4Z,6E)-1,7-bis(4-(4-bromobutoxy)-3-methoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one, C29H34O6Br2), was prepared and its two-photon absorption (TPA) properties were described in the femtosecond regime. The experimental results showed that complex I exhibited relatively strong and wide-dispersed two-photon activities in the near-infrared (NIR) regime and the calculated TPA cross section of complex I was as high as 872 GM (1 GM = 10−50 cm4 s photon−1) in DMF. Additionally, complex I revealed its potential application as a biological fluorescent probe due to its good photo-physical properties and low cytotoxicity, as well as excellent stability and specificity for optical imaging of tumors. Complex I was characterized by single crystal X-ray diffraction too (CIF file CCDC no. 1412447).